Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

December 3, 2025

Study Completion Date

November 3, 2027

Conditions
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Duvelisib

Given PO

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET

PROCEDURE

Punch Biopsy

Undergo punch biopsies

Trial Locations (17)

10065

NYP/Weill Cornell Medical Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33146

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

33442

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

55905

Mayo Clinic in Rochester, Rochester

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63136

Siteman Cancer Center at Christian Hospital, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

80045

UCHealth University of Colorado Hospital, Aurora

85054

Mayo Clinic Hospital in Arizona, Phoenix

32224-9980

Mayo Clinic in Florida, Jacksonville

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH